# Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

> **NCT07340541** · PHASE2 · RECRUITING · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 700 (estimated)

## Conditions studied

- Breast Cancer
- Metastatic Breast Cancer
- Triple Negative Breast Cancer
- Estrogen-receptor-positive Breast Cancer
- Hormone Receptor Negative Breast Carcinoma

## Interventions

- **DRUG:** SERD* + abemaciclib
- **DRUG:** SERD* + everolimus
- **DRUG:** SERD* + everolimus or capecitabine
- **DRUG:** SOC
- **DRUG:** Antiandrogen

## Key facts

- **NCT ID:** NCT07340541
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-16
- **Primary completion:** 2031-06-02
- **Final completion:** 2031-06-02
- **Target enrollment:** 700 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07340541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07340541, "Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07340541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*